Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CXCR4 AnTagonism for Cell Mobilisation and Healing in Acute Myocardial Infarction (CATCH-AMI). A Phase IIa, Double-Blind, Placebo-Controlled, Randomised, Multi-centre Study of POL6326, a CXCR4 Antagonist, in Patients With Large Reperfused ST Elevation Myocardial Infarction

NCT01905475 is registered in ClinicalTrials.gov with Polyphor Ltd. as lead sponsor.

NCT NCT01905475
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01905475 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CXCR4 AnTagonism for Cell Mobilisation and Healing in Acute Myocardial Infarction (CATCH-AMI). A Phase IIa, Double-Blind, Placebo-Controlled, Randomised, Multi-centre Study of POL6326, a CXCR4 Antagonist, in Patients With Large Reperfused ST Elevation Myocardial Infarction
Lead sponsor
Polyphor Ltd.
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2013
Completion date
June 30, 2016
Enrollment
120 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

large reperfused st-elevation myocardial infarction